4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholiopropylamino)quinoline | 320366-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholiopropylamino)quinoline
• 英文别名: 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholinopropylamino)quinazoline；4-(2-bromo-4-fluorophenoxy)-6-methoxy-N-(3-morpholin-4-ylpropyl)quinazolin-7-amine
• CAS: 320366-55-0
• 化学式: C₂₂H₂₄BrFN₄O₃
• 分子量: 491.36
• InChiKey: FOXXRDBKTSUHDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  68.7
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca UK Limited

  公开号：EP1218353A1

  公开（公告）日：2002-07-03
• USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1272185B1

  公开（公告）日：2005-07-27
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA UK LTD

  公开号：WO2001004102A1

  公开（公告）日：2001-01-18

  The invention concerns quinazoline derivatives of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
• [EN] THERAPY<br/>[FR] THERAPIE
  申请人：ASTRAZENECA AB

  公开号：WO2001066099A2

  公开（公告）日：2001-09-13

  The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
• [EN] QUINAZOLINES WITH THERAPEUTIC USE<br/>[FR] QUINAZOLINES A USAGE THERAPEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2002002534A1

  公开（公告）日：2002-01-10

  The invention concerns the use of quinazoline derivatives of Formula (I) wherein Q1 includes a qinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.